COMMUNIQUÉS West-GlobeNewswire

Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026
12/10/2026
- Interim Phase 3 findings will be presented in a prestigious late-breaking oral session at the leading meeting for kidney health professionals. – Randomized trial compares the acellular tissue engineered vessel (ATEV) [...]
Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery
12/10/2026
Portage, Mich., USA and Cambridge, England, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Strategic alliance combines CMR Surgical’s established platform and robotics expertise with Stryker’s scale, customer relationships and [...]
Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026
12/10/2026
New analysis projects VOQUEZNA® (vonoprazan) to provide meaningful economic value and be cost-effective vs. proton pump inhibitors (PPIs) for adults with Erosive GERD, with potential cost savings at net price based on [...]
STERIS Expands Healthcare Consumables Offering with Definitive Agreement to Acquire Xodus Medical, a Specialty Surgical Products Business Focused on Patient and OR Staff Safety
12/10/2026
Consumable product portfolio a natural extension for STERIS’s Healthcare Customers Compelling financial benefits: expected to be accretive to top-line growth, margins and adjusted earnings Anticipated to close by [...]
Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA® Initiation in Adults with IBS-C
12/10/2026
Additional presentations highlight the design of an ongoing Phase 3 study evaluating tenapanor in chronic idiopathic constipation and the impact of IBS-C symptom burden on quality of life WALTHAM, Mass., Oct. 12, 2026 ( [...]
Concept Life Sciences Appoints Dr Adrijana Vinter as Chief Executive Officer
12/10/2026
Experienced CRO leader brings deep scientific, commercial and operational expertise to lead the company’s next phase of growth CHAPEL-EN-LE-FRITH, United Kingdom, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Concept Life Sciences [...]
Aprocitentan efficacy data reinforce endothelin pathway blockade as a distinct therapeutic approach across the cardiometabolic disease spectrum including obesity
12/10/2026
Two oral presentations at AHA Hypertension 2026 demonstrate the pronounced efficacy of aprocitentan in two groups of patients with notoriously difficult to control hypertension from the PRECISION study: patients with [...]
InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China
12/10/2026
BEIJING, Oct. 11, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for [...]
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Granted FDA Fast Track Designation for First-Line Advanced or Metastatic Biliary Tract Cancer
12/10/2026
Second FDA Fast Track Designation for Opamtistomig Underscores Its Potential in Immunologically Cold Tumors NANJING, China, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “ [...]
Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records
11/10/2026
- In an independent, propensity score-matched analysis of 2,684 individuals living with ATTR-CM from Epic COSMOS, the largest U.S. electronic health record database, acoramidis was associated with a statistically [...]
First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026
11/10/2026
SAN DIEGO, Oct. 11, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in [...]
Cardurion Pharmaceuticals Presents Phase 2 Results for Tovinontrine (CRD-750), a PDE9 Inhibitor, as a Novel Treatment for Heart Failure
11/10/2026
In Cycle-1 REF Phase 2 clinical trial, tovinontrine demonstrated substantial reduction in NT-proBNP, a biomarker for heart failure, in patients with HFrEF on top of guideline-directed medical therapy, with a favorable [...]
Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1
11/10/2026
- Encaleret administration increased bone turnover, based on its action to recover endogenous PTH secretion in patients with ADH1 - 100% of participants who received encaleret reported improvements in at least one ADH1 [...]
Beyond Cholesterol Numbers: Dr. Wallace Brucker Brings AI-Powered Cardiac Plaque Screening to Las Vegas Executives at LV Longevity Lab
11/10/2026
LAS VEGAS, NV, Oct. 11, 2026 (GLOBE NEWSWIRE) -- Using FDA-cleared Cleerly AI analysis of coronary CT angiography, LV Longevity Lab looks directly at the arteries — settling whether plaque exists and personalizing [...]
Claris Biotherapeutics Releases Positive CSB-001 Clinical Proof-of-Concept Data in Limbal Stem Cell Deficiency at AAO 2026 Annual Meeting
11/10/2026
41% of CSB-001 treated eyes gained ≥15 letters compared to 0% in the non-treatment arm 55% of CSB-001 treated eyes gained ≥10 letters compared to 5% in the non-treatment arm Responses were durable, with 50% and 81% of [...]
Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026
11/10/2026
– Significant performance improvement seen across all subtypes of advanced precancerous lesions, which are important to detect for potential colorectal cancer prevention – – Overall detection of colorectal cancer [...]
Roche presents new Phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
10/10/2026
In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in patients with UME at 52 weeks 1,2 UME is the leading cause of moderate and severe [...]
LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress
10/10/2026
NEW YORK, Oct. 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that [...]
Corza Medical Launches Expanded Blink Single-Use Custom Packs and First-of-Its-Kind Microsurgical Knife Manufacturing Process
10/10/2026
BOULDER, Colo., Oct. 10, 2026 (GLOBE NEWSWIRE) -- Corza Medical, a leading global medical technology company, today announced the launch of its expanded Blink Single-Use Custom Packs offering and a first-of-its-kind [...]

Pages